Puma wins a big round in fight for neratinib OK as experts offer a crucial thumbs up
Puma Biotechnology $PBYI won a crucial vote in favor of its experimental breast cancer drug neratinib, with a majority of outside experts offering the FDA …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
